{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-026747","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.851585+00:00","generated_at":"2026-06-14T05:43:18.744235+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fate Therapeutics announces FDA clearance of FT522 IND for Phase 1 trial in B-cell lymphoma","bullets":["FDA allowed IND for FT522, an induced pluripotent stem cell-derived CAR NK-cell product candidate.","Phase 1 dose-escalating trial will assess FT522 plus CD20-targeted mAb in relapsed/refractory B-cell lymphoma.","Two regimens: with or without conditioning chemotherapy; starting dose 300M cells per dose in three-dose schedule.","Regimen A enrollment to begin first; Regimen B will start after DLT clearance at initial dose level.","Company presented update at 2023 Jefferies Healthcare Conference on June 7, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-026747","json":"https://secwatch.observer/filing/0000950170-23-026747.json","markdown":"https://secwatch.observer/filing/0000950170-23-026747.md","text":"https://secwatch.observer/filing/0000950170-23-026747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023026747/0000950170-23-026747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023026747/fate-20230607.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:43:18.744235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}